Selina Chen-Kiang, PhD

Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.

Chen-Kiang says the important part of using a CDK4/6 inhibitor is using combination therapies. For her trial, patients received a treatment combination of a CDK-4/6 inhibitor, palbociclib (Ibrance), plus the BTK inhibitor ibrutinib (Imbruvica).

Selina Chen-Kiang, PhD | Authors

Articles

A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell Lymphoma